Product was Nuo Therapeutics’s largest product and service line in fiscal 2025, bringing in $3.09M of $3.31M (93%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Product | $112.25K | $608.53K | $1.37M | $3.09M | |||
| License | — | — | — | $225.00K | |||
| Royalty | — | — | — | — | |||
| Total | $112.25K | $608.53K | $1.37M | $3.31M |
Nuo Therapeutics brought in $3.31M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Nuo Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.37M. Product was the largest at $3.09M (93.2%), ahead of License at $225.00K (6.8%).
Nuo Therapeutics (AURX) reports its revenue by product and service. In fiscal 2025, Product was its largest product and service line, bringing in $3.09M (93.2% of the total), followed by License at $225.00K (6.8%).
Product was Nuo Therapeutics' largest product and service line in fiscal 2025, bringing in $3.09M, or 93.2% of the $3.31M total across its two product and service lines.
Every figure comes from Nuo Therapeutics' annual financial filings, as reported. Each line keeps the name Nuo Therapeutics gives it, and years follow its fiscal calendar.
Nuo Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.